CG Oncology (CGON) Return on Sales: 2024-2025
Historic Return on Sales for CG Oncology (CGON) over the last 1 years, with Sep 2025 value amounting to -68.29%.
- CG Oncology's Return on Sales rose 3813.00% to -68.29% in Q3 2025 from the same period last year, while for Sep 2025 it was -68.29%, marking a year-over-year increase of 3813.00%. This contributed to the annual value of -77.30% for FY2024, which is 16067.00% up from last year.
- Latest data reveals that CG Oncology reported Return on Sales of -68.29% as of Q3 2025, which was up 57.18% from -159.48% recorded in Q1 2025.
- CG Oncology's 5-year Return on Sales high stood at -68.29% for Q3 2025, and its period low was -159.48% during Q1 2025.
- In the last 2 years, CG Oncology's Return on Sales had a median value of -88.08% in 2024 and averaged -97.94%.
- Over the last 5 years, CG Oncology's Return on Sales had its largest YoY gain of 3,813bps in 2025, and its largest YoY loss of 8,200bps in 2025.
- CG Oncology's Return on Sales (Quarterly) stood at -77.30% in 2024, then soared by 3,813bps to -68.29% in 2025.
- Its last three reported values are -68.29% in Q3 2025, -159.48% for Q1 2025, and -77.30% during Q4 2024.